Pfizer Cuts Costs by $7.2 Billion as New Product Sales Drive Growth

Key Facts

1New and acquired products generated $3.2 billion in Q2, growing 18% year-over-year.

2Pfizer has successfully removed $7.2 billion from its cost base.

3COVID revenue is expected to fall to $4 billion in 2026, reducing pressure on post-pandemic earnings.

Pfizer has successfully removed $7.2 billion from its cost base as part of its financial transformation strategy. Seeking Alpha reported that new and acquired products generated $3.2 billion in the second quarter, representing an 18% growth year-over-year. These measures aim to bolster earnings as the company transitions away from pandemic-era reliance.

PFE closed at $28.4 on October 12, 2026, as projections indicate COVID-related revenue will fall to $4 billion by 2026. This anticipated decline is expected to reduce pressure on post-pandemic earnings, supported by the company's optimization of its cost structure and focus on scaling new acquisitions.